Insider Selling: CeriBell (NASDAQ:CBLL) VP Sells 781 Shares of Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 781 shares of the stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $19.98, for a total value of $15,604.38. Following the completion of the sale, the vice president owned 17,550 shares in the company, valued at approximately $350,649. The trade was a 4.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

David Foehr also recently made the following trade(s):

• On Monday, February 23rd, David Foehr sold 569 shares of CeriBell stock. The shares were sold at an average price of $19.79, for a total value of $11,260.51.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $22.60, for a total transaction of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total transaction of $88,609.95.

CeriBell Stock Down 4.8%

Shares of CBLL traded down $0.95 during midday trading on Wednesday, reaching $18.95. The stock had a trading volume of 713,550 shares, compared to its average volume of 351,326. The company has a market cap of $703.05 million, a price-to-earnings ratio of -12.55 and a beta of 1.03. The company’s fifty day simple moving average is $21.26 and its two-hundred day simple moving average is $16.17. CeriBell, Inc. has a 1-year low of $10.01 and a 1-year high of $25.98. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. The company had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%. Equities research analysts expect that CeriBell, Inc. will post -2.46 earnings per share for the current year.

Wall Street Analyst Weigh In

CBLL has been the topic of several recent analyst reports. BTIG Research reiterated a “buy” rating and issued a $30.00 price target on shares of CeriBell in a research note on Wednesday, January 28th. JPMorgan Chase & Co. dropped their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Canaccord Genuity Group boosted their price target on shares of CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, CeriBell has an average rating of “Moderate Buy” and a consensus price target of $24.67.

Key CeriBell News

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

Institutional Trading of CeriBell

Several institutional investors and hedge funds have recently bought and sold shares of CBLL. Squarepoint Ops LLC acquired a new stake in shares of CeriBell during the second quarter worth about $1,054,000. Geode Capital Management LLC increased its position in CeriBell by 55.4% in the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after acquiring an additional 159,698 shares during the period. Emerald Mutual Fund Advisers Trust raised its stake in CeriBell by 58.2% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after acquiring an additional 57,175 shares during the last quarter. Police & Firemen s Retirement System of New Jersey lifted its position in CeriBell by 161.0% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after acquiring an additional 3,502 shares during the period. Finally, F m Investments LLC purchased a new position in shares of CeriBell in the 2nd quarter valued at approximately $381,000.

About CeriBell

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.